PSTV
Plus Therapeutics, Inc. NASDAQ Listed Jul 11, 2001$5.95
After hrs
$5.90
+0.85%
Mkt Cap $14.4M
52w Low $2.90
14.8% of range
52w High $23.50
50d MA $6.11
200d MA $11.17
P/E (TTM)
-0.8x
EV/EBITDA
-2.1x
P/B
4.7x
Debt/Equity
0.2x
ROE
-560.2%
P/FCF
-1.9x
RSI (14)
—
ATR (14)
—
Beta
1.02
50d MA
$6.11
200d MA
$11.17
Avg Volume
357.0K
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
4200 Marathon Boulevard · Austin, TX 78756 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.80 | -0.83 | -4.2% | 7.37 | -6.6% | -15.2% | +4.3% | -4.1% | -5.6% | +2.2% | — |
| Oct 30, 2025 | AMC | -0.02 | -0.04 | -100.0% | 13.25 | -1.7% | +2.5% | -4.7% | -1.6% | +7.0% | -5.7% | — |
| Aug 14, 2025 | AMC | -0.09 | -0.01 | +88.9% | 13.56 | +10.6% | +15.8% | -14.6% | -2.4% | -7.6% | -0.1% | — |
| May 30, 2025 | AMC | -0.25 | -0.56 | -125.7% | 7.17 | +40.7% | +28.2% | +3.0% | -6.9% | -9.5% | +2.0% | — |
| Mar 27, 2025 | AMC | -0.51 | -0.67 | -31.4% | 38.00 | -14.5% | -23.7% | -18.1% | +7.4% | -12.7% | -13.0% | — |
| Nov 14, 2024 | AMC | -0.56 | -0.37 | +34.2% | 31.50 | +1.6% | -7.1% | +1.7% | +4.2% | -4.0% | +0.8% | — |
| Aug 14, 2024 | AMC | -0.53 | -0.71 | -34.0% | 35.50 | +4.2% | -1.4% | -2.9% | +17.6% | -3.1% | -5.8% | — |
| May 15, 2024 | AMC | -1.09 | -0.75 | +31.2% | 58.00 | -4.3% | -3.0% | -0.4% | -2.7% | -2.3% | +2.3% | — |
| Mar 5, 2024 | AMC | -1.07 | -0.70 | +34.7% | 54.50 | -5.0% | -11.0% | -10.8% | -2.3% | -4.7% | +9.9% | — |
| Oct 31, 2023 | AMC | -0.58 | -1.00 | -72.4% | 30.50 | +8.2% | +5.7% | +5.4% | +17.6% | +0.3% | +5.9% | — |
| Aug 14, 2023 | AMC | -1.91 | -0.59 | +69.1% | 62.50 | +3.6% | -2.8% | -1.6% | -2.5% | +0.0% | -3.0% | — |
| Apr 20, 2023 | AMC | -2.10 | -2.10 | +0.0% | 116.25 | -6.5% | -16.1% | -3.8% | -8.0% | +0.0% | +8.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $3.17 | $3.13 | -1.3% | +23.7% | +22.4% | +12.7% | +0.4% | +4.1% |
| Mar 31 | D. Boral Capital | Downgrade | Buy → Hold | — | $5.37 | $4.15 | -22.7% | -24.4% | -3.9% | -8.7% | -6.5% | -12.3% |
| Mar 19 | D. Boral Capital | Maintains | Buy → Buy | — | $5.90 | $6.02 | +2.0% | +2.2% | +2.8% | -1.5% | -1.8% | +2.5% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.12 | $7.12 | +0.0% | -4.8% | -5.6% | -6.6% | +4.2% | -1.6% |
| Jan 22 | D. Boral Capital | Maintains | Buy → Buy | — | $7.30 | $7.75 | +6.2% | -2.5% | -4.8% | -5.6% | -6.6% | +4.2% |
| Jan 8 | D. Boral Capital | Maintains | Buy → Buy | — | $15.20 | $15.00 | -1.3% | -3.8% | -5.1% | -11.7% | -4.1% | -38.2% |
| Dec 11 | D. Boral Capital | Maintains | Buy → Buy | — | $16.81 | $16.80 | -0.1% | +7.1% | -5.0% | -8.7% | +2.0% | -9.0% |
| Dec 1 | D. Boral Capital | Maintains | Buy → Buy | — | $15.25 | $15.25 | +0.0% | -4.5% | +1.2% | +1.2% | +9.8% | -0.8% |
| Nov 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $12.21 | $12.30 | +0.7% | +9.1% | +8.0% | -2.5% | +6.7% | +1.9% |
| Nov 20 | D. Boral Capital | Maintains | Buy → Buy | — | $12.25 | $13.63 | +11.3% | -0.3% | +9.1% | +8.0% | -2.5% | +6.7% |
| Nov 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.58 | $13.68 | +0.7% | -4.7% | -1.6% | +7.0% | -5.7% | +4.7% |
| Oct 31 | D. Boral Capital | Maintains | Buy → Buy | — | $13.25 | $13.03 | -1.7% | +2.5% | -4.7% | -1.6% | +7.0% | -5.7% |
| Oct 21 | D. Boral Capital | Maintains | Buy → Buy | — | $14.48 | $16.53 | +14.2% | +7.0% | -4.8% | +7.7% | -3.1% | -2.1% |
| Oct 6 | Ascendiant Capital | Maintains | Buy → Buy | — | $18.28 | $19.00 | +3.9% | +21.7% | -7.7% | -9.1% | -3.2% | -3.5% |
| Sep 25 | D. Boral Capital | Maintains | Buy → Buy | — | $10.11 | $15.55 | +53.8% | +39.3% | +9.6% | +34.7% | -17.8% | -0.8% |
| Sep 22 | D. Boral Capital | Maintains | Buy → Buy | — | $10.39 | $11.00 | +5.9% | +1.8% | -4.5% | +0.1% | +39.3% | +9.6% |
| Sep 18 | D. Boral Capital | Maintains | Buy → Buy | — | $10.42 | $10.51 | +0.9% | +3.5% | -3.6% | +1.8% | -4.5% | +0.1% |
| Sep 3 | D. Boral Capital | Upgrade | Hold → Buy | — | $10.69 | $11.00 | +2.9% | +7.6% | -2.3% | +9.3% | -2.8% | +3.2% |
| Aug 18 | Maxim Group | Maintains | Buy → Buy | — | $15.70 | $14.50 | -7.6% | -14.6% | -2.4% | -7.6% | -0.1% | +0.5% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.16 | $8.00 | -12.7% | -14.0% | +10.4% | -10.9% | -0.9% | -3.5% |
| Jun 25 | D. Boral Capital | Maintains | Hold → Hold | — | $4.68 | $9.90 | +111.5% | +68.4% | +16.2% | -14.0% | +10.4% | -10.9% |
| Jun 5 | Ascendiant Capital | Maintains | Buy → Buy | — | $8.82 | $8.53 | -3.3% | -9.5% | +2.0% | +7.0% | +0.5% | -5.7% |
| May 5 | D. Boral Capital | Downgrade | Buy → Hold | — | $16.20 | $15.49 | -4.4% | -4.3% | -19.4% | +12.7% | +10.0% | +6.5% |
| Apr 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $16.47 | $16.43 | -0.2% | -2.7% | +22.8% | +24.9% | -14.3% | -6.5% |
| Mar 28 | D. Boral Capital | Maintains | Buy → Buy | — | $38.00 | $32.50 | -14.5% | -23.7% | -18.1% | +7.4% | -12.7% | -13.0% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.00 | $32.50 | -14.5% | -23.7% | -18.1% | +7.4% | -12.7% | -13.0% |
| Mar 21 | D. Boral Capital | Maintains | Buy → Buy | — | $34.50 | $27.50 | -20.3% | -14.5% | -3.4% | +25.4% | +2.8% | +3.4% |
| Dec 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $34.75 | $34.50 | -0.7% | -2.9% | -3.0% | +3.1% | -1.5% | -4.5% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.75 | $31.50 | +2.4% | +4.1% | -1.6% | +1.6% | +0.8% | +3.9% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.50 | $32.00 | +1.6% | -7.1% | +1.7% | +4.2% | -4.0% | +0.8% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.00 | $35.25 | +0.7% | -2.9% | +17.6% | -3.1% | -5.8% | -2.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.50 | $64.75 | +3.6% | -2.8% | -1.6% | -2.5% | +0.0% | -3.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.50 | $64.00 | +2.4% | +0.0% | -2.8% | -1.6% | -2.5% | +0.0% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.50 | $64.75 | +5.3% | -17.9% | +1.0% | +3.9% | +0.0% | +4.7% |
| May 3 | Maxim Group | Maintains | Buy → Buy | — | $92.50 | $90.00 | -2.7% | +1.4% | +2.4% | +3.9% | +5.5% | +9.3% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $191.25 | $206.25 | +7.8% | +3.9% | +0.0% | -3.8% | -2.0% | +2.0% |
No insider trades available.
8-K · 8.01
!! High
PLUS THERAPEUTICS, Inc. -- 8-K 8.01: Material Event / Announcement
Plus Therapeutics implemented a 1-for-25 reverse stock split effective April 2, 2026, consolidating shares to improve stock price and potentially enhance market compliance.
Apr 21
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A leadership transition at these biotech/pharma companies could signal strategic shifts in R&D priorities or pipeline management, potentially affecting stock valuations depending on the departing executive's role and successor's experience.
Apr 9
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
PSTV received FDA Orphan Drug Designation for REYOBIQ in pediatric brain cancer, enabling extended market exclusivity and potential tax credits, meaningfully reducing competitive and regulatory risk for this rare indication.
Apr 8
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I don't have access to the actual press release content or announcement details from this 8-K filing, so I cannot write a specific analyst sentence about what this means for PSTV stock.
To help you properly, please share either:
- The specific announcement/material event described
- Key details from the press release
- What business development occurred
Then I can provide a
Apr 2
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced diagnostics executive joining PostiveID (PSTV) as a leader strengthens management credibility and operational capability, potentially improving execution in the diagnostics sector.
Mar 26
8-K
Unknown — 8-K Filing
Plus Therapeutics reported 2025 results and outlined 2026 milestones for its REYOBIQ clinical program and CNSide commercial rollout, suggesting progress toward revenue generation and potential market expansion that could drive stock appreciation.
Mar 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
PSTV announced stockholder proposal submission deadlines under SEC Rule 14a-8 and company bylaws, signaling an upcoming proxy season where investors can formally challenge management or propose board changes.
Mar 12
8-K · 5.02
!!! Very High
PLUS THERAPEUTICS, Inc. -- 8-K 5.02: Executive Change
Plus Therapeutics appointed executive officers to its board of directors, strengthening internal oversight and potentially signaling management confidence in the company's strategic direction.
Feb 13
Data updated apr 26, 2026 9:05pm
· Source: massive.com